Managed Healthcare Executive Newsletter

ASCO Program

Taking Aim at TIGIT, a New Immunotherapy Approach to Non-Small Cell Lung Cancer

The 2020 annual meeting of the American Society of Clinical Oncology that launches today will feature the first results from CITYSCAPE, a trial involving a novel immunotherapy approach in non-small cell lung cancer (NSCLC). This phase 2 trial is the first to combine the immunotherapy tiragolumab with atelzolizumab (Tecentriq), the monoclonal antibody that targets the programmed cell death ligand-1 (PD-L1).

MURANO Shows Worse Outcomes in R/R CLL When Venetoclax is Stopped Early

A fresh look at MURANO data, released this week at the American Society of Clinical Oncology 2020 Annual meeting, shows the poor outcomes that result when patients halt treatment for good, and highlight the need to manage doses carefully to avoid toxicity.

Anna Lee Shares ASCO Study on Changes in Cancer Mortality Rates (VIDEO)

Anna Lee, lead author of the Abstract: Changes in Cancer Mortality Rates After the Adoption of the Affordable Care Act, discusses her study with MHE. Lee presented her study May 29 during ASCO 2020's virtual conference.

Sara Douglas Discusses ASCO Study on Distance Caregiving (VIDEO)

Sara Douglas, lead investigator of the Abstract: Video Conference Intervention for Distance Caregivers (DCGs) of Patients with Cancer: Improving Psychological Outcomes, discusses her study with MHE's Briana Contreras which will be presented at ASCO 2020.